Hemab Therapeutics closed a $157 million financing to advance a portfolio of programs addressing rare coagulation disorders, including plans to start a pivotal trial of sutacimig in Glanzmann thrombasthenia next year. Investors led by Sofinnova Partners joined other crossover and strategic backers, giving the company capital to push its lead candidates through clinical inflection points. Hemab positioned the raise as enabling a focused commercial path for underserved bleeding disorders — a space that has seen slower innovation compared with hemophilia. The funding will support pivotal studies and broader pipeline programs, and positions Hemab to capitalize on rising interest in specialty hematology assets that address high‑unmet‑need rare diseases.